PHRMAG appoints new Executive Committee for 2025–2027
Founded in 2005, PHRMAG represents 29 leading global biopharmaceutical research companies in the region. Dedicated to advancing innovation and patient care, the association collaborates with health authorities and healthcare systems to enhance access to treatments while ensuring transparency and ethical conduct through its globally aligned Code of Ethics.
The newly appointed EC includes Sameh Elfangary, as Chairman and Cluster President at AstraZeneca GCC & Pakistan; Ashraf Mallak, Vice Chairman and Managing Director GCC at MSD; Ahmed Abu El Fadl, EC Member and General Manager Gulf at Merck Serono; Diederik Kok, EC Member and Head of GCC at Biogen; Elhussein Abdellatif, EC Member and General Manager Gulf Levant at AbbVie Biopharmaceuticals GmbH; Mazen Bachir, the former Chairman and now serving as EC Member and Regional Director Gulf, Levant & Emerging Markets at Abbott; and Pedro Matos Rosa, EC Member and General Manager at Johnson & Johnson Innovative Medicines Gulf.
Sameh Elfangary, the newly appointed Chairman, said "I am both honored and humbled to lead PHRMAG's Executive Committee for the 2025–2027 term. On behalf of the member companies, I would like to extend our gratitude to the former Chairman, Mazen Bachir and the outgoing EC for their invaluable leadership contributions over the last couple of years, which further builds on the solid 20-year foundation of PHRMAG. The healthcare ecosystem in our region is undergoing fast-paced transformation, bringing novel mix of opportunities and challenges. As we move forward, together we will collaborate to shape an even more thriving future, and we will remain dedicated to the PHRMAG's mission of fostering innovation, sustaining an equitable patient access to life-changing care, while we continue championing transparency and integrity.'
Key achievements of PHRMAG's 2023–2025 term and Executive Committee include strengthening industry collaboration with key stakeholders such as the Emirates Drug Establishment (EDE) and the Department of Health Abu Dhabi to advance sustainable healthcare initiatives. The outgoing committee successfully engaged in pivotal events like Abu Dhabi Global Healthcare Week and the BIO International Convention, reinforcing the Gulf region's position as a leader in pharmaceutical innovation.
PHRMAG's Working Groups also made significant contributions during this term, driving impactful initiatives across various areas. The Ethics & Compliance Working Group continued to champion ethical practices, fostering trust and transparency throughout the industry. The IP Policy Working Group made considerable strides in emphasizing on intellectual property frameworks and facilitating dialogue on regulatory policies to enable access to innovative treatments. Notably, in 2024, one of PHRMAG's collaborations included partnering with the U.S. Chamber of Commerce and the GCC Patent Office to host a pivotal roundtable on the state of intellectual property in the GCC, highlighting the critical role of robust IP protections in shaping the region's patent ecosystem.
PHRMAG extends its gratitude to the outgoing committee for their tireless efforts and dedication to advancing healthcare in the Gulf. Their leadership has significantly impacted the pharmaceutical landscape, creating a lasting legacy of innovation and progress.
-Ends-
About PHRMAG
The Pharmaceutical Research and Manufacturers Association Gulf (PHRMAG) was founded in 2005 and represents 29 of the leading global innovative biopharmaceutical research companies in the Gulf region. Our member companies are devoted to innovating and developing medicines that enable patients to live longer, healthier, and more productive lives.
PHRMAG's mission is to foster relationships with health authorities and healthcare systems to enhance provisions for patients and create a transparent environment for biopharmaceutical companies. Based on our globally-aligned Code of Ethics, we ensure responsible and transparent conduct. We shape the future of healthcare, improve patient outcomes, and enhance the value of the biopharmaceutical industry to drive progress in the Gulf Region.
PHRMAG is committed to partnering with policymakers to support innovative medical research, yield progress for patients of today, and provide hope for the treatments and cures of tomorrow across the Gulf Region. For more information about PHRMAG and its initiatives, please visit https://phrmag.com/
Media Contact (Agency)
Nausheen.Shamsher@proglobal.ae
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Middle East Eye
6 days ago
- Middle East Eye
European Commission considers suspending Israel's access to EU funding for tech start-ups
The European Commission (EC) on Monday said it is considering suspending Israel's access to European Union (EU) funding for tech start-ups, following pressure over the humanitarian situation in Gaza, AFP reported. A string of EU countries have pushed for concrete action against Israel in the face of growing fears of mass starvation in the war-ravaged territory. The proposed action would involve partially suspending Israel's involvement in the Horizon research programme and will be discussed by the EU's 27 countries on 29 July. It would need the approval of the majority of member states to go into force. "The situation remains severe," the EC said in a statement. "The proposed suspension is a targeted and reversible action," it added. The EU has been criticised for not doing enough to end Israel's war on Gaza.
Al Etihad
21-07-2025
- Al Etihad
GSK Regional Vaccine Distribution Hub in Abu Dhabi receives first shipments
21 July 2025 11:20 ABU DHABI (ALETIHAD)The Department of Health – Abu Dhabi (DoH) has announced the operational launch of the region's vaccine distribution hub in Abu Dhabi, following the arrival of the facility's first in Abu Dhabi and developed in partnership with leading global and regional stakeholders, the hub is a strategic milestone in the emirate's vision to strengthen global health security, ensure equitable vaccine access, and build resilient supply chains across the in KEZAD and operated by Rafed, a subsidiary of PureHealth, the hub was developed in collaboration with the DoH, Abu Dhabi Investment Office (ADIO), GSK, AD Ports Group, Etihad Cargo, and KEZAD is a cornerstone of the UAE's expanding life sciences ecosystem and is designed to improve vaccine access across the hub leverages Abu Dhabi's strategic location, its advanced cold-chain logistics infrastructure, and a regulatory environment that is both agile and supportive of innovation. This hub reflects Abu Dhabi's model of cross-sector collaboration, uniting government, biopharma, logistics, and innovation under one activation of the hub follows a strategic agreement signed between DoH and GSK during Abu Dhabi Global Healthcare Week in 2024 to establish regional vaccine distribution capabilities in the realised, the facility becomes GSK's first vaccine distribution centre in the Middle East and the fourth worldwide, further solidifying Abu Dhabi's role in supporting regional health security and global supply chain hub's activation also marks one of the first major operational milestones under HELM – Abu Dhabi's Life Science Cluster, which was officially launched in April 2025 during Abu Dhabi Global Health the emirate's flagship platform to drive life sciences investment, innovation, and global collaboration, HELM brings together government, industry, and academia to strengthen Abu Dhabi's position as a preferred global partner in precision health, pharmaceutical manufacturing, and biopharma logistics. The hub's integration under HELM demonstrates how Abu Dhabi is translating its life sciences vision into operational outcomes that drive regional impact. Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said, 'The operational launch of Abu Dhabi's regional vaccine hub signals our readiness to serve the region with speed, precision, and reliability. More than a logistics milestone, this reflects our long-term vision to position Abu Dhabi as a trusted partner in global health where innovation and resilience translate into timely access and measurable public health impact. Through this hub, we are making vaccines more accessible to communities across borders and strengthening the UAE's leadership in preventive, future-ready healthcare.'The facility will manage a portfolio of more than 20 vaccines, including those for paediatric and adult populations, supporting lifelong immunisation strategies across multiple markets. Designed for scalability, the hub can accommodate emerging vaccine technologies and increased regional demand while maintaining the highest global quality and safety President and General Manager, GSK Gulf, Boyd Chongphaisal, said, 'The launch of our vaccine distribution hub in Abu Dhabi represents a shared commitment to health security, innovation, and access. Through our strategic partnership with DoH and local stakeholders, we are combining scientific excellence with operational strength to ensure the timely, efficient delivery of vaccines across the region. The integration of this hub under HELM further demonstrates GSK's pioneering stance and alignment with Abu Dhabi's vision for driving impactful outcomes in the life sciences sector on a regional and global scale. This initiative is also a testament to Abu Dhabi's position in the global value chain, strengthening its role in global health and innovation.'Rafed, the operator of the facility, has deployed advanced cold-chain and smart distribution technologies that preserve vaccine integrity and ensure end-to-end visibility throughout the logistics process. The hub is fully integrated with Etihad Cargo's PharmaLife network, which connects Abu Dhabi to more than 100 international destinations and offers time-sensitive, temperature-controlled freight services tailored for pharmaceutical Executive Officer of Rafed, Mohammad Mustafa Saeed, said, 'As a PureHealth company, Rafed is committed to delivering healthcare excellence through world-class pharmaceutical logistics. The launch of this regional vaccine distribution hub is a tangible expression of our strategy to strengthen health systems, improve access, and build resilience across borders. By deploying advanced cold-chain and smart distribution technologies, we are enabling real-time, end-to-end visibility. We remain focused on supporting governments and health partners with confidence and reliability to achieve better health outcomes for communities from Abu Dhabi across the Middle East, Africa, and South Asia.'The facility is expected to distribute millions of doses annually, shortening delivery timelines across the region and improving the integrity of vaccine Cargo Officer at Etihad Airways, Stanislas Brun, said, 'Etihad Cargo's participation in this initiative reflects our continued investment in healthcare logistics. Our network and specialised PharmaLife product play a critical role in transporting temperature-sensitive vaccines reliably and efficiently across the region. We are proud to support Abu Dhabi's vision of becoming a global leader in life sciences and supply chain excellence.'The facility's activation significantly strengthens Abu Dhabi's life sciences value chain and supports its ambition to serve as a global hub for innovation-led, knowledge-based industries. Its operational readiness will help improve vaccine access, reduce delivery lead times, and address public health needs through a more proactive and resilient healthcare model.
Al Etihad
08-07-2025
- Al Etihad
Abu Dhabi leads high-level delegation to US, showcasing emirate's global leadership in healthcare innovation
8 July 2025 13:10 ABU DHABI (ALETIHAD)Department of Health – Abu Dhabi (DoH) has led a high-level delegation on a strategic mission to the US to strengthen partnerships and showcase Abu Dhabi's excellence in life sciences and precision visit reflected the emirate's global leadership in healthcare innovation and its commitment to international cooperation to advance scientific research, innovation, and ethical medical delegation visited key US cities including Boston, Washington DC, and Philadelphia, in parallel with Abu Dhabi's participation at BIO International Convention 2025, one of the world's foremost biotechnology visit spotlighted the emirate's achievements in AI, digital health, genomics, and clinical research, and showcased Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Life Science Cluster, while promoting long-term strategic partnerships with government entities, research institutions, and global Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of DoH, said: 'This mission demonstrated Abu Dhabi's ongoing efforts to cement its position as a global centre of excellence in health and life sciences. We are committed to fostering partnerships that advance healthcare innovation and enhance quality of life, both in the UAE and globally.'The delegation conducted more than 20 strategic meetings and visits with public and private sector leaders across the US, aimed at enhancing knowledge exchange and investment opportunities, and marked the signing of new agreements that will accelerate the adoption of advanced health mission facilitated joint actions between DoH and global organisations set to shape the future of healthcare. These alliances reinforce the Emirate's steadfast dedication to advancing health outcomes through impactful global collaborations, pioneering research and a robust infrastructure that fosters innovation, talent and investment. Key agreements and partnerships were formed with prestigious US-based peers and partners, including the University of California, San Francisco, the Innovative Genomics Institute, Sanofi, Boehringer Ingelheim, Abbott, Aetna International, GEMMABio and Children's National Hospital. These collaborations focus on establishing genome surgery centres, advancing vaccine development and manufacturing, integrating innovative research platforms and localising pharmaceutical production, while also expanding access to US healthcare networks, developing genomics and biotechnology research centres and launching advanced cell and gene therapy programmes for the side-lines of Abu Dhabi's participation at BIO International Convention in Boston, USA, the Department of Health – Abu Dhabi, in collaboration with Johnson & Johnson (J&J) and Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the UAE for serious and complex care and a subsidiary of the PureHealth group, have successfully enabled expedited access to Tremfya®, a next-generation biologic medication for patients with Inflammatory Bowel Disease (IBD). This strategic partnership marks the first availability of the treatment outside the United States, reinforcing Abu Dhabi's position as a as a pioneering destination for healthcare innovation and advanced, patient-focused Abu Dhabi's innovation ecosystem, the delegation included key stakeholders such as Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD Group, PureHealth, StartAD, Khalifa University, New York University Abu Dhabi, and Etihad Dhabi continues to lead the region in genomics through the Emirati Genome Programme, which has successfully sequenced more than 800,000 samples, creating one of the most advanced national genomic databases. The emirate is also home to more than 90 licensed research centres and over 30 ongoing clinical trials in areas such as oncology, rare diseases, and chronic data platforms such as Malaffi, which securely store over 5 million patient records—enable AI-powered insights and real-world evidence, while national initiatives like the Golden Visa have enabled more than 2,000 long-term visas for researchers and healthcare professionals from around the world. This strategic visit reflected Abu Dhabi's broader vision for healthcare transformation—driven by innovation, investment, and a deep commitment to global collaboration.
